Search

everythinglearnresearchcommunity

for

Search:↓

Non-myeloablative stem cell transplants are a promising, less toxic option for older or weaker patients, with fewer side effects and good outcomes.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

A man developed autoimmune issues after a transplant, improved with treatment, but died from leukemia relapse.

A man got six skin cancers within a year after a cell transplant for leukemia but was cancer-free 32 months later; skin checks are important post-transplant.

Busulfan/cyclophosphamide and total bone irradiation are equally effective for AML transplants.

Skin problems are common after stem cell transplants, and early treatment by dermatologists can improve patient outcomes.

A woman's hair loss from graft versus host disease helps understand similar hair loss conditions.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Entospletinib effectively prevents eye and skin GVHD in mice.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Exosomes could potentially enhance tissue repair and regeneration with lower rejection risk and easier production than live cell therapies.

Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.

People with allergies or high eosinophil levels have a higher chance of severe hair loss from alopecia areata, and sudden hair loss can indicate chronic graft-versus-host disease.

Skin issues from chronic graft-versus-host disease greatly affect daily life, needing teamwork between blood and skin doctors.

The patient's long-term hair loss was caused by leukemia treatments and low estrogen levels, worsened by her genetic tendency for hair loss.

Both methods improve hair density and thickness; double-spin may be more effective.

Palliative chemotherapy is cost-effective for advanced gastric and colorectal cancer but not clearly for pancreatic-biliary cancer.

Some children who had stem cell transplants developed permanent hair loss, especially when treated with a drug called busulphan.

Skin issues can indicate immune system problems.

People with late-stage HIV-1 often experience a specific type of hair loss linked to multiple factors, including nutritional issues and immune responses.

Skin and mucous membrane issues are common in kids after bone marrow transplants, so careful monitoring is crucial.

Permanent hair loss after bone marrow transplant can be caused by chemotherapy or chronic graft-versus-host disease.

Skin changes like hair loss, white patches, and nail changes are common in children after bone marrow transplants, often linked to chronic rejection.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Mice with human fetal thymic tissue and stem cells developed symptoms similar to chronic graft-versus-host disease.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

Transplant success has improved with better immunosuppressive drugs and donor matching.

ASC-CM is more effective than EV for treating osteoarthritis.

M50054 may help treat hepatitis and hair loss from chemotherapy.

Stem cell therapy is promising for treating various health conditions, but more research is needed to understand its full potential and address challenges.